Metronomic chemotherapy and nanocarrier platforms

Lila, Amr S. Abu; Ishida, Tatsuhiro

doi:10.1016/j.canlet.2016.11.007

Cited by 18 publications

(10 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incorporating a large number of low doses in MC contrasts with the traditional “more is better” dosing approach used in MTD approach 46 . On the other hand, MC, as a monotherapy, has not been able to provide convincing results in clinical trials 20 , 21 . Till now, it could be used in just some phase III cases of breast cancer, head and neck tumors, colorectal cancer, and hepatocellular carcinoma 21 .…”

Section: Discussionmentioning

confidence: 97%

“…Till now, it could be used in just some phase III cases of breast cancer, head and neck tumors, colorectal cancer, and hepatocellular carcinoma 21 . Its combination with other drugs like Bevacizumab and Pazopanib, other therapeutic approaches such as radiotherapy, and/or encapsulation of chemotherapeutic agents in nanoparticles have been shown to potentiate treatment outcomes 20 , 22 . Single large doses (i.e., MTD) could be deemed necessary in cases where the dose windows are small, but might be less efficient for new targeted drugs with lower toxicity 30 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach

Kashkooli

Soltani

2021

Sci Rep

View full text Add to dashboard Cite

The development of an in silico approach that evaluates and identifies appropriate treatment protocols for individuals could help grow personalized treatment and increase cancer patient lifespans. With this motivation, the present study introduces a novel approach for sequential treatment cycles based on simultaneously examining drug delivery, tumor growth, and chemotherapy efficacy. This model incorporates the physical conditions of tumor geometry, including tumor, capillary network, and normal tissue assuming real circumstances, as well as the intravascular and interstitial fluid flow, drug concentration, chemotherapy efficacy, and tumor recurrence. Three treatment approaches—maximum tolerated dose (MTD), metronomic chemotherapy (MC), and chemo-switching (CS)—as well as different chemotherapy schedules are investigated on a real tumor geometry extracted from image. Additionally, a sensitivity analysis of effective parameters of drug is carried out to evaluate the potential of using different other drugs in cancer treatment. The main findings are: (i) CS, MC, and MTD have the best performance in reducing tumor cells, respectively; (ii) multiple doses raise the efficacy of drugs that have slower clearance, higher diffusivity, and lower to medium binding affinities; (iii) the suggested approach to eradicating tumors is to reduce their cells to a predetermined rate through chemotherapy and then apply adjunct therapy.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach

Kashkooli

Soltani

2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The aim of metronomic therapy to administer a reduced but prolonged dose coincides with one of the main benefits of drug carriers [224]. The development of vehicles that "package" therapeutic agents allows the delivery of a lower dosage in a "nanometronomic" manner [225], while overcoming the obstacles presented by free drugs as regards alleviating systemic toxicity and side effects, increasing tumor penetration, and sustained drug release [226][227][228]. Indeed, by choosing the most suitable pharmacological vehicle for the therapeutic agent, the latter can be protected, its solubility increased, and its release modulated by prolonging the time of circulation and reducing the dosage [229].…”

Section: Simulated Metronomic Therapies: Nanocarriers For Cancer Therapymentioning

confidence: 99%

“…Furthermore, many other possible metronomic-based therapies are being studied. In this regard, promising results have been attained upon combining metronomic therapy with an NC drug formulation [227,254] in melanoma [255], and colorectal [254], prostate [256], and ovarian cancer [257], thereby demonstrating how these two strategies can synergistically improve cancer treatment. To achieve metronomic dosing for ovarian cancer therapy, Amoozgar et al have developed bilayer coated NCs to both extend paclitaxel release and improve the ability of NCs to hide from the immune system, thereby enhancing their blood circulation half-life.…”

Section: Simulated Metronomic Therapies: Nanocarriers For Cancer Therapymentioning

confidence: 99%

Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment

Muñoz

Girotti

Hileeto

et al. 2021

Cancers

View full text Add to dashboard Cite

The concept of cancer as a systemic disease, and the therapeutic implications of this, has gained special relevance. This concept encompasses the interactions between tumor and stromal cells and their microenvironment in the complex setting of primary tumors and metastases. These factors determine cellular co-evolution in time and space, contribute to tumor progression, and could counteract therapeutic effects. Additionally, cancer therapies can induce cellular and molecular responses in the tumor and host that allow them to escape therapy and promote tumor progression. In this study, we describe the vascular network, tumor-infiltrated immune cells, and cancer-associated fibroblasts as sources of heterogeneity and plasticity in the tumor microenvironment, and their influence on cancer progression. We also discuss tumor and host responses to the chemotherapy regimen, at the maximum tolerated dose, mainly targeting cancer cells, and a multimodal metronomic chemotherapy approach targeting both cancer cells and their microenvironment. In a combination therapy context, metronomic chemotherapy exhibits antimetastatic efficacy with low toxicity but is not exempt from resistance mechanisms. As such, a better understanding of the interactions between the components of the tumor microenvironment could improve the selection of drug combinations and schedules, as well as the use of nano-therapeutic agents against certain malignancies.

show abstract

“…One challenge with metronomic therapy is that stimulation of the immune response is not only dose and schedule dependent, but also depends on the chemotherapeutic agent employed. Some chemotherapeutic agents seem to increase immune-response, while others do the opposite [ 28 , 29 ]. For the chemotherapeutics that increase immune-response and induce immunogenic cell death, metronomic administration can improve the efficacy of immune checkpoint inhibition [ [30] , [31] , [32] ].…”

Section: Introductionmentioning

confidence: 99%

Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy

Mpekris

Voutouri

Panagi

et al. 2022

Journal of Controlled Release

View full text Add to dashboard Cite

Metronomic chemotherapy and nanocarrier platforms

Cited by 18 publications

References 101 publications

Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach

Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach

Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment

Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy

Contact Info

Product

Resources

About